Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
Public ClinicalTrials.gov record NCT00517192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.
Study identification
- NCT ID
- NCT00517192
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Aug 31, 2008
- Completion
- Not listed
- Last update posted
- May 13, 2014
Started 2007
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1182.71.1109 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1182.71.1101 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1182.71.1104 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1182.71.1115 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1182.71.1108 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1182.71.1126 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1182.71.1124 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1182.71.1116 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1182.71.1118 Boehringer Ingelheim Investigational Site | Longview | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00517192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00517192 live on ClinicalTrials.gov.